Discounted Cash Flow (DCF) Analysis Unlevered

ProQR Therapeutics N.V. (PRQR)

$0.8011

-0.03 (-3.19%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.8011 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.8,011
Beta 0.793
Diluted Shares Outstanding 50.06
Cost of Debt
Tax Rate -0.09
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.540
Total Debt 60.37
Total Equity 40.10
Total Capital 100.48
Debt Weighting 60.09
Equity Weighting 39.91
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.08%0.52%0.24%-0.16%-0.09%0.12%0.12%0.12%0.12%0.12%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.12-0.31-0.58-0.92-0.48-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 5.61
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -127.15
Equity Value -
Shares Outstanding 50.06
Equity Value Per Share -